Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Summary

To evaluate the safety of a single intramuscular (IM) injection of trivalent adjuvanted influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody response to each influenza vaccine antigen, as measured by single radial hemolysis (SRH) and hemagglutination inhibition (HI) at approximately 21 days postimmunization in elderly subjects in compliance with the requirements of the current EU recommendations for clinical trials related to yearly licensing of influenza vaccines.

Timeline

Start

2012-07

Primary completion

2012-08

Completion

2012-08

Drugs

Indications